Skip to content

Anna Schuldt

3 papers in the library · 354 citations · publishing 2023-2025

Papers

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.

EClinicalMedicine February 1, 2023 Robin von Rotz, Eva M Schindowski, Johannes Jungwirth et al. 345 citations

A single, moderate dose of psilocybin (0.215 mg/kg body weight) significantly reduced depressive symptoms compared to placebo in adults with major depressive disorder. Over two weeks, depression severity scores dropped by 13.0 points on the MADRS and 13.2 points on the BDI in the psilocybin group, with improvements significantly larger than in the placebo group. 54% of participants receiving psilocybin met remission criteria. No serious adverse events occurred. The findings suggest psilocybin offers rapid antidepressant effects, though larger, longer-term trials are needed.

DOI: 10.1016/j.eclinm.2022.101809 Full text Depression Major depressive disorder Psychedelic-assisted therapy Magic mushrooms +8

Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.

EClinicalMedicine February 1, 2023 Robin von Rotz, Eva M Schindowski, Johannes Jungwirth et al. 8 citations correction

A correction was issued for a figure in a clinical trial on psilocybin-assisted therapy for major depressive disorder. The colors representing the Psilocybin and Placebo conditions were swapped in Fig. 2; the correction aligns them with the caption and other figures. The error does not affect the results. The trial found that a single, moderate dose of psilocybin significantly reduces depressive symptoms compared to placebo for at least two weeks, with no serious adverse events. Larger, multi-centric trials with longer follow-up are needed to optimize this treatment.

DOI: 10.1016/j.eclinm.2023.101841 Full text Psilocybin Depression Correction Clinical trials +1

Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.

Healthcare (Basel) September 12, 2025 Anna Schuldt, Ian C. Clark, Yasmin Schmid et al. 1 citation

Experts in palliative care, oncology, psychiatry, and psychedelic-assisted therapy identified special considerations for using psychedelics near the end of life. They emphasized a non-medicalized setting, the potential to reduce preparation time, and the importance of addressing anxiety, depression, and spiritual distress. Dosing flexibility was recommended: low-to-medium doses for relational issues, higher doses for transcendental experiences. Therapists need knowledge of mystical states, existential aspects of life-threatening illness, and their own inner work. The findings provide a first step toward specific treatment recommendations for psychedelic-assisted therapy in palliative care.

DOI: 10.3390/healthcare13182275 Full text Psychedelic therapy Psychedelics Psychedelic-assisted treatment Entheogenic therapy +18